Preventing Anthracycline Cardiovascular Toxicity With Statins (PREVENT)
Status:
Completed
Trial end date:
2020-09-24
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to see if Atorvastatin(Lipitor) 40 mg by mouth daily
decreases the chance of developing heart problems in women receiving adjuvant
anthracycline-based chemotherapy for breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Wake Forest University Health Sciences
Collaborators:
National Cancer Institute (NCI) National Heart, Lung, and Blood Institute (NHLBI)